In vivo effect of interferon-β 1a on interleukin-12 and TGF-β1 cytokines in patients with relapsing-remitting multiple sclerosis

被引：24

作者：

Losy, J

Michalowska-Wender, G

机构：

[1] Univ Sch Med, Dept Clin Neuroimmunol, PL-60355 Poznan, Poland

[2] Polish Acad Sci, Inst Ctr Expt & Clin Med, Neuroimmunol Unit, Poznan, Poland

来源：

ACTA NEUROLOGICA SCANDINAVICA | 2002年 / 106卷 / 01期

关键词：

multiple sclerosis; interferon-beta; 1a; interleukin-12; TGF-beta; 1;

D O I：

10.1034/j.1600-0404.2002.01209.x

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

We have studied in vivo effect of interferon-beta 1a (IFN-beta 1a) (6 MIU once weekly i.m.) on interleukin-12 (IL-12) and transforming growth factor-beta(1) (TGF-beta(1) ) serum levels during 6 months of therapy in group of 20 patients with relapsing-remitting multiple sclerosis (MS). IL-12 and TGF-beta(1) concentrations were measured by enzyme linked immunoabsorbent assay (ELISA). There was a significant increase of IL-12 levels in MS patients in comparison with control group, suggesting a role of this cytokine in immunity of MS. We have also found a significant increase of TGF-beta(1) levels after 6 months of therapy with IFN-beta 1a, however, there was no in vivo effect of the therapy on IL-12 levels. The results suggest that IFN-beta 1a may exert its action through up- regulation and increase secretion of TGF-beta(1) .

引用

页码：44 / 46

页数：3

共 22 条

[1] INTERFERONS AND MULTIPLE-SCLEROSIS [J].

ARNASON, BGW ;

REDER, AT .

CLINICAL NEUROPHARMACOLOGY, 1994, 17 (06) :495-547

[2]

Bartholomé EJ, 1999, ACTA NEUROL BELG, V99, P44

[3] Transforming growth factor β1 (TGFβ1) mRNA level correlates with magnetic resonance imaging disease activity in Multiple Sclerosis patients [J].

Bertolotto, A ;

Capobianco, M ;

Malucchi, S ;

Manzardo, E ;

Audano, L ;

Bergui, M ;

Bradac, GB ;

Mutani, R .

NEUROSCIENCE LETTERS, 1999, 263 (01) :21-24

[4] Profile of cerebrospinal fluid and serum cytokines in patients with relapsing-remitting multiple sclerosis: A correlation with clinical activity. [J].

Carrieri, PB ;

Provitera, V ;

De Rosa, T ;

Tartaglia, G ;

Gorga, F ;

Perrella, O .

IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 1998, 20 (03) :373-382

[5]

Carrieri PB, 1997, NEUROL RES, V19, P599

[6]

Constantinescu CS, 1998, J IMMUNOL, V161, P5097

[7] Increased release of interleukin-12p40 in MS - Association with intracerebral inflammation [J].

Fassbender, K ;

Ragoschke, A ;

Rossol, S ;

Schwartz, A ;

Mielke, O ;

Paulig, A ;

Hennerici, M .

NEUROLOGY, 1998, 51 (03) :753-758

[8] Interleukin-12 is detectable in sera of patients with multiple sclerosis - association with chronic progressive disease course? [J].

Heesen, C ;

Sieverding, F ;

Schoser, BGH ;

Hadji, B ;

Kunze, K .

EUROPEAN JOURNAL OF NEUROLOGY, 1999, 6 (05) :591-596

[9] Intramuscular interferon beta-1 alpha for disease progression in relapsing multiple sclerosis [J].

Jacobs, LD ;

Cookfair, DL ;

Rudick, RA ;

Herndon, RM ;

Richert, JR ;

Salazar, AM ;

Fischer, JS ;

Goodkin, DE ;

Granger, CV ;

Simon, JH ;

Alam, JJ ;

Bartoszak, DM ;

Bourdette, DN ;

Braiman, J ;

Brownscheidle, CM ;

Coats, ME ;

Cohan, SL ;

Dougherty, DS ;

Kinkel, RP ;

Mass, MK ;

Munschauer, FE ;

Priore, RL ;

Pullicino, PM ;

Scherokman, BJ ;

WeinstockGuttman, B ;

Whitman, RH ;

Baird, WC ;

Fillmore, M ;

Bona, LM ;

ColonRuiz, ME ;

Nadine, BS ;

Donovan, A ;

Bennett, S ;

Kieffer, YM ;

Umhauer, MA ;

Miller, CE ;

Kilic, AK ;

Sargent, EL ;

Schachter, M ;

Shucard, DW ;

Weider, V ;

Catalano, BA ;

Cervi, JM ;

Czekay, C ;

Farrell, JL ;

Filippini, JS ;

Matyas, RC ;

Michienzi, KE ;

Ito, M ;

OMalley, JA .

ANNALS OF NEUROLOGY, 1996, 39 (03) :285-294

[10] Interferon β in multiple sclerosis:: is IL-12 suppression the key? [J].

Karp, CL ;

Biron, CA ;

Irani, DN .

IMMUNOLOGY TODAY, 2000, 21 (01) :24-28

← 1 2 3 →